Literature DB >> 33661995

LncRNA LINC00857 strengthens the malignancy behaviors of pancreatic adenocarcinoma cells by serving as a competing endogenous RNA for miR-340-5p to upregulate TGFA expression.

Tingfu Li1, Hongbo Zhao2, Hua Zhou3, Tingting Geng4.   

Abstract

BACKGROUND: Pancreatic adenocarcinoma (PAAD) is a pancreatic disease with a high mortality rate in the world. This present research intends to identify the function of lncRNA LINC00857/miR-340-5p/Transforming growth factor alpha (TGFA) in the progression of PAAD.
METHODS: Bioinformatics analysis was used to explore the differentially expressed lncRNA/miRNA/mRNA and analyze the relationship between lncRNA/miRNA/mRNA expression and prognosis of PAAD by enquiring TCGA, GEO and GTEX. KEGG pathway analysis and GO enrichment analysis were implemented to annotate the crucial genes regulated by LINC00857. The biological behaviors of PAAD cells were detected by CCK-8, colony formation and transwell assays. Interactive associations between LINC00857 and miR-340-5p, as well as miR-340-5p and TGFA were analyzed by dual luciferase assay.
RESULTS: By enquiring TCGA database, we got that LINC00857 was highly expressed in patients with PAAD and positively associated with worse prognosis in PAAD patients. Moreover, LINC00857 upregulation promoted the proliferation and clone formation abilities of PAAD cells. Afterwards, the downstream miRNA and mRNA targets of LINC00857 were picked up to construct a ceRNA network. Further study revealed that TGFA expression was positively regulated by LINC00857 and negatively regulated by miR-340-5p. Besides that, the inhibitory effect of miR-340-5p on PAAD cells growth and movement can be blocked by LINC00857 upregulation. While, the malignant behavior of PAAD cells induced by TGFA overexpression can be eliminated by LINC00857 knockdown.
CONCLUSIONS: Upregulation of LINC00857 improved growth, invasion and migration abilities of PAAD cells by modulation of miR-340-5p/TGFA, affording potential targets and biomarkers for the clinical diagnosis and treatment.

Entities:  

Year:  2021        PMID: 33661995      PMCID: PMC7932076          DOI: 10.1371/journal.pone.0247817

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  36 in total

1.  LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial-mesenchymal transition.

Authors:  Chaofeng Xia; Xiao-Yu Zhang; Wenhui Liu; Man Ju; Yingdong Ju; Yan-Zhi Bu; Weixing Wang; Hongjin Shao
Journal:  J Cell Biochem       Date:  2018-12-03       Impact factor: 4.429

Review 2.  Role of microRNA (miRNA) and Viroids in Lethal Diseases of Plants and Animals. Potential Contribution to Human Neurodegenerative Disorders.

Authors:  L Cong; Y Zhao; A I Pogue; W J Lukiw
Journal:  Biochemistry (Mosc)       Date:  2018-09       Impact factor: 2.487

Review 3.  Competitive endogenous RNA in colorectal cancer: A systematic review.

Authors:  Han Shuwen; Zhou Qing; Zheng Yan; Yang Xi
Journal:  Gene       Date:  2017-12-19       Impact factor: 3.688

4.  Up-regulation of miR-340-5p promotes progression of thyroid cancer by inhibiting BMP4.

Authors:  P Zhao; W Ma; Z Hu; Y Zhang; S Zhang; Y Wang
Journal:  J Endocrinol Invest       Date:  2018-02-13       Impact factor: 4.256

5.  Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression.

Authors:  Shasha Bi; Yan Wang; Hu Feng; Qingchang Li
Journal:  Cell Cycle       Date:  2020-03-01       Impact factor: 4.534

6.  EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.

Authors:  Yisun Jeong; Soo Youn Bae; Daeun You; Seung Pil Jung; Hee Jun Choi; Isaac Kim; Se Kyung Lee; Jonghan Yu; Seok Won Kim; Jeong Eon Lee; Sangmin Kim; Seok Jin Nam
Journal:  Cell Physiol Biochem       Date:  2019

Review 7.  The regulatory roles of long noncoding RNAs in the biological behavior of pancreatic cancer.

Authors:  Ying Li; Xiaojuan Yang; Xiaoning Kang; Shanglong Liu
Journal:  Saudi J Gastroenterol       Date:  2019 May-Jun       Impact factor: 2.485

Review 8.  Role of non-coding RNA in pancreatic cancer.

Authors:  Yinghao Lv; Shuai Huang
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

Review 9.  The role of miRNA and lncRNA in gastric cancer.

Authors:  Ning-Bo Hao; Ya-Fei He; Xiao-Qin Li; Kai Wang; Rui-Ling Wang
Journal:  Oncotarget       Date:  2017-07-12

10.  Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma.

Authors:  Yalu Zhang; Rundong Zhang; Guopei Luo; Kaixing Ai
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

View more
  5 in total

1.  LINC00857 promotes the proliferation of pancreatic cancer via MET, STAT3, and CREB.

Authors:  Ye Song; Yingying Liang; Qingfeng Zou; Shaoting Zeng; Hanhong Lin; Meiyuan Liu; Xiaoyan Liu; Jike Du; Guoan Chen; Lei Zou; Wenmei Su; Feiyu Niu
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  LncRNA LINC01857 drives pancreatic adenocarcinoma progression via modulating miR-19a-3p/SMOC2.

Authors:  Yeting Lu; Dongjian Ying; Yuan Tian; Yi Ruan; Gong Cheng; Kaiji Lv; Xinhua Zhou; Shuo Han
Journal:  Clinics (Sao Paulo)       Date:  2022-06-02       Impact factor: 2.898

3.  Identification and Validation of Apparent Imbalanced Epi-lncRNAs Prognostic Model Based on Multi-Omics Data in Pancreatic Cancer.

Authors:  Mujing Ke
Journal:  Front Mol Biosci       Date:  2022-05-12

Review 4.  The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer.

Authors:  Xiaoge Hu; Xiangxiang Lei; Jinhui Guo; Wen Fu; Wen Sun; Qiliang Lu; Wei Su; Qiuran Xu; Kangsheng Tu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

5.  Identification of a prognostic classifier based on EMT-related lncRNAs and the function of LINC01138 in tumor progression for lung adenocarcinoma.

Authors:  Lingyan Xiao; Yongbiao Huang; Qian Li; Sheng Wang; Li Ma; Zhijie Fan; Zhe Tang; Xianglin Yuan; Bo Liu
Journal:  Front Mol Biosci       Date:  2022-08-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.